Bispecific Antibody Competitive Landscape Analysis: Strategic Intelligence Covering 180+ Companies And 250+ Therapeutic Candidates

DelveInsight report provides in-depth analysis of the rapidly evolving bispecific antibody domain

Published on Feb. 6, 2026

Got story updates? Submit your updates here. ›

DelveInsight, a prominent life sciences–focused market research and business consulting firm, has announced the launch of its newest report titled 'Bispecific Antibody – Competitive Landscape'. The comprehensive analysis delivers in-depth strategic insights into the rapidly evolving bispecific antibody domain, profiling more than 180 companies and over 250 drug candidates.

Why it matters

The bispecific antibody market spans major global regions, with strong R&D activity concentrated in the United States, Europe, and the Asia-Pacific region. As regulatory pathways mature and next-generation modalities emerge, bispecific antibodies are expected to transform oncology care while expanding into autoimmune, neurological, and rare disease indications.

The details

Biopharmaceutical companies worldwide continue to advance innovative bispecific antibody–based therapies, achieving notable developmental progress over recent years. The oncology-focused bispecific antibody pipeline assessment estimates the addressable patient population across multiple indications, including Acute Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Multiple Myeloma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Biliary Tract Cancer, Breast Cancer, Gastric and Esophageal Cancers, Pancreatic Cancer, Colorectal Cancer, and other malignancies.

  • The report was published on February 6, 2026.

The players

I-MAB Biopharma

A biopharmaceutical company developing innovative bispecific antibody therapies.

Bristol Myers Squibb

A global biopharmaceutical company with a focus on developing bispecific antibody treatments.

AstraZeneca

A multinational pharmaceutical and biotechnology company with a bispecific antibody pipeline.

BioNTech

A German biotechnology company advancing bispecific antibody candidates.

Genmab

A biotechnology company that has developed the DuoBody® platform for bispecific antibodies.

Got photos? Submit your photos here. ›

The takeaway

The bispecific antibody competitive landscape analysis highlights the rapid advancements in this field, with numerous companies and drug candidates poised to transform the treatment of various diseases, particularly in the oncology space. The report provides valuable insights for stakeholders to stay informed and capitalize on emerging opportunities in the bispecific antibody market.